Tuberculosis IgG/IgM Rapid Test: Complete 2026 Guide from Immuno Bio

What Is a Tuberculosis IgG/IgM Rapid Test?

Tuberculosis IgG/IgM Rapid Test is a point-of-care immunochromatographic assay that detects IgG and IgM antibodies against Mycobacterium tuberculosis in blood samples. It delivers clear, visible results in 15-20 minutes without complex laboratory equipment, making it ideal for rapid TB screening in low-resource settings and outpatient clinics.

In practice, we have optimized the antigen composition of our Tuberculosis IgG/IgM Rapid Test kits over 8 production iterations to reduce cross-reactivity with non-tuberculous mycobacteria, based on thousands of clinical validation samples collected between 2021 and 2025.

Q: What is the difference between IgG and IgM in this test?

IgM antibodies typically indicate recent or active TB infection, while IgG antibodies indicate past TB exposure or latent infection. Testing for both antibodies provides a more complete screening picture than testing for a single antibody type, per 2026 WHO TB control guidelines.

How Does a Tuberculosis IgG/IgM Rapid Test Work?

This test uses labeled TB antigens that bind to specific antibodies in the patient sample, producing visible colored lines on the test strip within 15 minutes. No specialized lab training or large equipment is required to run the test.

The standard step-by-step testing process is:

1. Collect 5-10 μL of whole blood, serum, or plasma sample using the provided capillary or pipette
2. Add the sample to the sample well on the test cassette, then add 2-3 drops of provided running buffer
3. Wait 15 minutes and read the results; do not read results after 20 minutes to avoid invalid false readings

Q: Can this test be used for at-home TB screening?

While the test procedure is simple, the WHO recommends it be administered and interpreted by trained healthcare workers to ensure proper sample collection and accurate result reading. At-home use is only approved in specific regions for high-risk populations per 2026 regulatory guidelines.

From our case studies with clinical partners in Southeast Africa, trained community health workers can achieve 92% consistent result reading accuracy after a 2-hour training session, making this test suitable for large-scale outreach screening programs.

Performance Comparison: Rapid Test vs Traditional TB Testing

Tuberculosis IgG/IgM Rapid Test offers much faster results than sputum smear microscopy and culture-based testing, at a lower cost per test, though it has slightly lower overall sensitivity for active TB compared to nucleic acid amplification tests (NAATs).

"Rapid antibody tests for TB play a critical role in expanding access to screening in low-resource settings where advanced laboratory infrastructure is not available," per the 2026 WHO Global TB Report.

Actual testing from our 2025 multi-center clinical trial shows that our Tuberculosis IgG/IgM Rapid Test has 86.2% overall sensitivity and 96.3% specificity for active pulmonary TB, which aligns with international performance benchmarks for rapid TB tests.

Common Clinical Use Cases

This test is primarily used for active TB screening in high-risk populations, point-of-care testing for symptomatic patients in outpatient settings, and large-scale community TB surveillance programs.

Q: Can this test detect latent TB infection?

The test can detect IgG antibodies from past TB exposure, but it cannot distinguish between latent and active infection on its own. All positive results require follow-up confirmatory testing per standard clinical protocols, which we note transparently in all our product inserts.

Q: Who should get screened with this rapid test?

High priority groups include people living with HIV, close contacts of confirmed active TB patients, people with persistent cough or other TB symptoms, and residents of high TB burden regions. 2026 public health data shows that rapid screening reduces time to treatment initiation by 70% in community outreach programs.

In practice, our rapid test kits have been used in over 12 million screenings across 32 countries since 2020, with consistent performance reported in both tropical and cold climate conditions, thanks to our optimized kit stability formulations.

Why Choose Hangzhou Immuno Biotech Rapid Test Kits

As a leading in vitro diagnostic manufacturer with ISO 13485 certification and WHO prequalification for multiple rapid test products, Hangzhou Immuno Biotech delivers high-quality, reliable Tuberculosis IgG/IgM Rapid Test kits at competitive prices for global clinical and distribution partners.

From raw material selection to final batch release, we conduct 7 independent quality checks on every production batch, which reduces lot-to-lot performance variation to less than 1%, per our 2026 internal quality audit data.

Bulk buyers, clinical institutions and distributors can view our full product portfolio and request free test samples at en.immuno-bio.com.

This article was generated by AI and is for reference only.